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S U M M A R Y
The international community has responded to the Ebola outbreak in West Africa with a ‘top down’
approach. This has contributed to outbreak control, but has done much less to reduce the high mortality
rate in individual patients. Ebola patients experience a breakdown in endothelial barrier integrity that
leads to massive ﬂuid losses and vascular collapse. Statins and angiotensin receptor blockers (ARBs)
maintain or restore endothelial barrier integrity. Local physicians in Sierra Leone have treated
approximately 100 consecutive Ebola patients with atorvastatin and irbesartan, and all but two
inadequately treated patients have survived. The results of this experience have not been released and
they need to be reviewed and validated. Unlike other treatments that target the Ebola virus itself, this
‘bottom up’ approach to treatment represents a paradigm shift by targeting the host response to
infection. Treatment with these safe, inexpensive generic agents could be implemented readily
throughout West Africa.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The international community has responded to the Ebola
outbreak in West Africa with an approach that could be described
as ‘top down’. Small groups of elite scientists, health policy makers,
pharmaceutical company executives, and the staff of the World
Health Organization (WHO), governmental agencies, and non-
governmental institutions have decided how to implement
interventions for outbreak control and containment and develop
new Ebola vaccines and treatments. These ‘top down’ interven-
tions have built Ebola treatment units and organized the delivery
of supplies, communications, and surveillance that have been
essential for outbreak control. However, they have had only a
modest impact on the survival rate for individual patients. In most
treatment units, overall case fatality rates have been 60% or
greater, and they have been even higher in patients who have been
treated in the community.1
Studies in non-human primates have shown that experimental
antiviral agents and antibody preparations reduce Ebola virus* Corresponding author.
E-mail address: dfedson@wanadoo.fr (D.S. Fedson).
http://dx.doi.org/10.1016/j.ijid.2015.04.019
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).replication and prolong or improve survival, and clinical trials of
several of these agents have begun in West Africa. These trials are
supported by hundreds of millions of dollars provided by
companies, governmental agencies, and foundations in developed
countries. However, by themselves, these agents will probably not
have a major impact on the high case fatality rate of Ebola. Early
results from a clinical trial of one antiviral agent (favipiravir)
suggest that compared to historical controls, overall mortality was
reduced by less than 20%.2 If Ebola survival rates are to improve
signiﬁcantly, something else will be needed.
2. Lessons learned from evacuated healthcare workers
Four foreign healthcare workers in West Africa were infected
with the Ebola virus and evacuated to the USA and European
countries. Reports of their treatment have provided new insight
into the pathophysiology of human Ebola virus disease.3–5 These
patients developed severe internal and external ﬂuid losses that
signalled a breakdown in endothelial barrier integrity (plasma
leak syndrome). Left untreated, these losses would have led to
vascular collapse, multi-organ failure, and death. Fortunately,
these patients received meticulous care, and all survived.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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care, including intravenous ﬂuid replacement, and consequently
mortality is high. The observations on the evacuated healthcare
workers suggest that if a simple treatment could be found that
maintains or restores normal endothelial barrier integrity, patient
survival might improve dramatically. Unlike antiviral agents, this
treatment would not target the Ebola virus; instead, it would target
the host response to infection.
3. Treating the host response to Ebola virus disease
Treating the host response to a disease is not a new idea. For
example, almost all cardiovascular diseases are not caused by
acute bacterial or viral infections, so treatment must target the
damage caused by the disease itself. Cardiovascular scientists have
developed several drugs that do this, and they include statins and
angiotensin receptor blockers (ARBs). Statins were initially
thought to work because they lower blood levels of low-density
lipoprotein (LDL) cholesterol, and ARBs were developed to treat
hypertension. Yet both drugs have anti-inﬂammatory activities,6,7
and both are known to maintain or restore endothelial barrier
integrity.8–11
More than a decade ago, Ebola scientists noted similarities
between human Ebola virus disease and sepsis.12,13 Increased
vascular permeability, multi-organ failure, and a high mortality are
found in both diseases.12–15 Many severe virus infections share the
same characteristics.16 Endothelial dysfunction is central to the
pathophysiology of sepsis and many viral diseases. Experimental
evidence strongly indicates that it is also central to theFigure 1. Ebola virus infection and endothelial dysfunction. Ebola viruses initially
infect myeloid cells, which release numerous pro-inﬂammatory cytokines. These
cytokines target endothelial cells, destabilize the actin cytoskeleton, and damage
adherens and tight junctions, leading to a loss of endothelial barrier integrity,
internal and external ﬂuid losses, and vascular collapse. (From Roca et al.18).pathophysiology of human Ebola virus disease.17 Figure 1 illus-
trates the endothelial effects of Ebola virus infection.18
Observational studies have shown that in patients hospitalized
with community-acquired pneumonia19 and seasonal inﬂuenza,20
treatment with either a statin or an ARB signiﬁcantly reduces all-
cause mortality within the next 30 days. More directly, a
randomized controlled trial conducted in 100 statin-naı¨ve patients
who were hospitalized with sepsis showed that treatment with
atorvastatin (40 mg/day) led to an 83% reduction in evidence of
multi-organ dysfunction.21 Experimental evidence indicates clear-
ly that sepsis-related multi-organ dysfunction can be prevented
and survival increased by stabilizing endothelial function alone.22
Numerous clinical studies have shown that statin and ARB
treatment of patients with sepsis, pneumonia, and inﬂuenza is
safe and well tolerated. Moreover, combined treatment with both
agents has been shown to have a greater effect on biomarkers of
inﬂammation and endothelial function than using either agent by
itself.23,24
These experimental and clinical ﬁndings suggest that treatment
with a statin, an ARB, or a combination of both, might improve
survival in Ebola patients.25
4. A trial of statin and ARB treatment of Ebola virus disease
In November this past year, thanks to a private donation by one
of the authors of this report (OMR), local physicians in Sierra Leone
were able to treat approximately 100 Ebola patients with a
combination of a statin and an ARB. Patients were treated in
several centres: the Port Loko Government Hospital, the 34 Military
Hospital in Freetown, the Hastings Ebola Treatment Centre, and a
few other locations. Treatment consisted of administering
atorvastatin (40 mg) and irbesartan (150 mg) daily for six or more
days, along with the usual care provided in Ebola treatment units.
(Several patients were also treated with clomiphene (50 mg/day)
for the ﬁrst 3 days. Clomiphene has been shown to have antiviral
activity against Ebola virus.26 Its effects on endothelial dysfunction
are not known.) Only two inadequately treated patients died. One
was extremely ill when ﬁrst seen and he died after only 1 or 2 days
of treatment. The other was a physician who was treated with
atorvastatin and irbesartan for 3 days and showed improvement.
His treatment was then stopped and he was started on an
experimental antiviral treatment, following which he relapsed and
died. All of the other (approximately 100) treated patients
survived. A memorandum written by one of the treating physicians
noted their ‘remarkable improvement’ on treatment (D.S. Fedson;
unpublished observation).
A clinical study of Ebola virus patients seen during the 2000–
2001 outbreak of Sudan Ebola virus disease showed that viral loads
were higher in patients who died compared with those who
survived, but starting on days 5–7, viral loads in both groups
started to decline (Figure 2).27 Recently, clinicians in Liberia
reported that the large volume watery diarrhoea in Ebola patients
rarely persisted beyond day 7 of illness, and clinical improvement
in survivors was noticeable a few days later.28 An important study
of Ebola patients evacuated to Atlanta in the USA showed that
instead of immunosuppression, these patients had robust humoral
and cellular immune responses.29 Taken together, these studies
help us understand the effects of atorvastatin and irbesartan
treatment. These agents maintained or restored endothelial barrier
integrity, shutting down excessive ﬂuid losses and preventing
vascular collapse. By prolonging survival, treatment allowed
patients to live long enough to develop an immune response
and eliminate the virus on their own. This outcome was achieved in
almost all treated patients without requiring the use of one of the
experimental antiviral agents now being tested in West Africa.
Figure 2. Ebola virus load (mean log10 RNA copies per ml of serum) in 18 survivors and 27 non-survivors of Sudan Ebola virus disease in 2000–2001. Viral loads started to
decline in both survivors and non-survivors 5–7 days after the onset of clinical symptoms. (From Towner et al.27).
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in Sierra Leone on the condition that (1) local ofﬁcials would
approve of their use, (2) healthcare professionals would keep
accurate treatment records, and (3) the results would be made
public, regardless of outcome. Unfortunately, there was no
ﬁnancial or logistical support for organized clinical trials, so
patients were treated consecutively. Treatment results were
documented informally and reported in letters and memoranda
exchanged among local physicians and health ofﬁcials. These
communications included individual treatment records for
15 patients (Table 1; D.S. Fedson, unpublished observation). The
clinical and treatment records of all treated patients need to be
examined in order to validate the results. Unfortunately, this has
not been possible because local supervising health ofﬁcials have
refused to release information on the treatment.
The idea of treating the host response has not been supported
by Ebola scientists and health ofﬁcials who have deﬁned the
international response to Ebola virus disease.30,31 They are
sceptical about a treatment based largely on an extrapolation of
ﬁndings obtained in other conditions like sepsis, pneumonia, and
inﬂuenza. They are uncertain about treatment safety and its effects
on virus replication. They insist on ﬁrst obtaining evidence of
treatment efﬁcacy in animal models of Ebola virus disease, andTable 1
Summary of treatment for 15 Ebola patients in the Port Loko Government
Hospitala,b
Patient Age/sex Duration of
treatment, days
1 30 F 5
2 30 F 4c
3 40 M 5c
4 10 F 4c
5 12 M 5c
6 25 F 6
7 23 F 6
8 12 F 6
9 20 F 6
10 42 F 8
11 12 F 6
12 35 M 6
13 45 F 6
14 20 F 8
15 15 M 6
a Summary of 15 individual patient treatment records. Five patients were
admitted on November 21, 2014 and 10 were admitted on November 25, 2014. All
patients survived. They were discharged either home (n = 5) or to a holding unit
(n = 10) to await a negative Ebola test result.
b All patients were treated with atorvastatin (40 mg/day) and irbesartan
(150 mg/day). In addition, all patients received clomiphene (50 mg/day) for the
ﬁrst 3 days of treatment.
c Patient received an additional day of clomiphene treatment.these interventions target only the virus. This approach to clinical
development has been sanctioned by the WHO and underlies all of
the clinical trials of antiviral agents now underway in West
Africa.32 Only agents that have shown promise in non human
primates (NHPs) are considered for human clinical trials. Ebola
scientists have used only rhesus macaques to test candidate
agents. This approach is unlike that of other investigators who have
shown that different NHP species respond differently to infection
with the same virus. For example, simian immunodeﬁciency virus
infection of rhesus macaques is uniformly fatal, whereas sooty
mangabeys all survive, although viral loads in both are the same.33
Most important, no NHP model of Ebola virus disease has
reproduced the endothelial dysfunction and ﬂuid losses seen in
human patients.34 Nonetheless, the reluctance of Ebola scientists
to target the host response remains. The results of statin and ARB
treatment of Ebola patients in Sierra Leone suggest that their
concerns are misplaced.
5. Treating the host response with statins and ARBs represents
a ‘bottom up’ approach to managing Ebola virus disease
The Ebola outbreak is West Africa is regarded as a major
humanitarian crisis.35 The outbreak was unrecognized for several
months, and then it was met with denial and hesitation by both
local and international health ofﬁcials.36 When foreign healthcare
workers became infected and were evacuated, the international
response changed rapidly. Extensive population-based measures
have achieved a large degree of outbreak control. Similarly
extensive efforts to provide clinical care for individual Ebola
patients have achieved much less.
The Editor of this journal recently noted that lower case fatality
rates in some Ebola treatment units appear to be associated with
the greater use of intravenous ﬂuids.37,38 He called for new
treatment guidelines that emphasize the principles of ﬂuid
replacement and the correction of electrolyte imbalance ‘‘that
can be implemented under ﬁeld conditions in West Africa,
provided staff are trained in high volume ﬂuid replacement’’.37
Others have also called for similar changes.39–41 One group of
investigators with experience in West Africa commented, ‘‘the
most important aspect of supportive care is aggressive prevention
of intravascular volume depletion, correcting profound electrolyte
abnormalities, and preventing the complications of shock. This is
an underlying tenant (sic) of critical care medicine, and one that
can and should be applied in both resource-constrained and
resource-rich settings . . .’’.39 They added, ‘‘with more personnel,
basic monitoring and supportive treatment, many of the sickest
patients with Ebola virus disease do not need to die. Ebola virus
disease represents an illness ready for a paradigm shift in care
delivery and outcomes . . .’’.39
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paradigm shift. By correcting the fundamental pathophysiological
abnormality caused by Ebola virus infection, these agents should
greatly reduce the need for intravenous ﬂuids, and this should
increase caregiver safety. All physicians in West Africa who treat
patients with heart disease and high blood pressure should be
familiar with their use and safety. Treating Ebola patients with
these orally administered agents would require no additional
training, personnel, or equipment. Debates over whether to
provide intensive organ support (e.g., mechanical ventilation,
renal dialysis) would become largely unnecessary.42–44 Statins and
ARBs are produced as inexpensive generics by companies located
in developing countries. A 10-day course of combination treatment
for an individual patient should cost no more than a few dollars
(D.S. Fedson; unpublished observation).
Treating Ebola patients with inexpensive generic agents like
statins and ARBs represents a ‘bottom up’ alternative to patient
management.45 Instead of relying on experimental agents that
might not dramatically improve survival,2,46 or those not yet
developed,47 it would rely on generic drugs that are widely
available in West Africa. Treatment could be implemented readily
for all patients who are treated by healthcare workers in Ebola
treatment units or by family members who care for patients at
home. These agents might also be used prophylactically to prevent
severe disease in healthcare workers and other contacts who
inadvertently become infected. They would provide caregivers
with a simple treatment that could be used in settings that have
little else to offer, radically transforming the management of Ebola
patients. They would even call into question the need for expensive
new treatments that target the Ebola virus.
6. A need for change
The WHO and all of the agencies and institutions involved in the
Ebola response have an obligation to obtain the best scientiﬁc
advice if they are to carry out their missions. For the Ebola
response, this means seeking advice not only from Ebola scientists,
but also from scientists in other disciplines; for example,
endothelial cell biology, ﬂuid and electrolyte metabolism, cell
signalling effects of statins, ARBs and other generic agents, and the
clinical and epidemiological effects of these agents in other forms
of acute critical illness. It means being open to the idea that an
effective treatment might target the host response, not the virus.
By establishing the ‘proof of principle’ that treating the host
response can be effective, this approach might be applied to patient
care for other emerging and re-emerging diseases,48 including an
avian inﬂuenza pandemic.45,49,50
The German physicist Max Planck once wrote, ‘‘A new scientiﬁc
truth does not triumph by convincing its opponents and making
them see the light, but rather because its opponents eventually die,
and a new generation grows up that is familiar with it.’’ In other
words, science advances one funeral at a time. This might be
acceptable if it meant only the funerals of scientists themselves. It
is a different matter if it means the funerals of many others.
In West Africa, more than 10 000 patients have died since early
August 2014, when WHO declared Ebola a public health
emergency of international concern and Ebola scientists and
WHO staff ﬁrst learned about the possibility of inexpensive generic
treatment.25,30 More than 4000 patients have died since late
November, when physicians and health ofﬁcials in Sierra Leone
observed the effectiveness of atorvastatin and irbesartan treat-
ment.
Clinical trials of agents like statins and ARBs should be part of
current efforts to confront Ebola virus disease in West Africa. A trial
protocol that includes atorvastatin and irbesartan treatment has
recently been approved,51 but a decline in the number of cases maymake it difﬁcult to undertake.52 If pockets of Ebola virus disease
persist, investigators must do everything possible to ensure that
this trial goes forward. If the number of new cases declines even
further, it will be critical for the results of the November treatment
experience in Sierra Leone to be independently analyzed and
validated. Only then will we be certain that treating the host
response to Ebola virus disease really works.
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